Please sign in to follow a disease.
Lab-Grown tumor clones could guide cancer therapy
NCT ID NCT04261192
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study aims to grow miniature versions of head and neck tumors, called organoids, from patient samples. Researchers will test different cancer drugs on these organoids to see which ones work best. The goal is to eventually use this approach to tailor treatments to each patient, potentially improving outcomes and reducing side effects. The study involves 120 adults with advanced squamous cell carcinoma of the head and neck who are scheduled for surgery.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- What this could lead to
- If successful, this could lead to a lab test that helps doctors choose the most effective treatment for each patient, reducing unnecessary side effects.
- What could go wrong
- This is an early-stage study focused on building organoids, not testing treatments on people. It may not lead to immediate changes in patient care.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
About 120 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Jul 2020
- Expected to finish
-
Feb 2032
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
Patient with squamous cell carcinoma of the oral cavity, oropharynx, hypopharynx or larynx, classified T3Nx or T4Nx or T2N +, not previously treated;
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Patient over 18 years of age; * Patient with squamous cell carcinoma of the oral cavity, oropharynx, hypopharynx or larynx, classified T3Nx or T4Nx or T2N +, not previously treated; * Patient to be treated by surgery; * Patient affiliated to a social security scheme; * No opposition to participate in the study Exclusion Criteria: * Pregnant woman ; * Persons deprived of their liberty or under guardianship (including curatorship); * History of malignant pathology preceding inclusion (apart from basal cell carcinomas of the skin and carcinomas in situ of the cervix treated surgically) or concomitant at inclusion (synchronous tumor)
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Head and neck cancer are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
2 sites. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
CHU de Caen
RECRUITINGCaen, France
-
Centre François Baclesse
RECRUITINGCaen, 14076, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a dental assistant keep cancer Patients' mouths healthier during radiation?
- Why do Non-Smokers get head and neck cancer? scientists probe tumor DNA
- Re-irradiation plus cetuximab targets head and neck tumors that return
- Sharper tumor maps: PET scans could tighten radiation beams
- Glowing dye lights up throat tumors during surgery
- Lighting up oral cancer: dye may help surgeons see tumor edges